Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Dihydrocodeine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 12/20 | 0.77 |
| ▸ | OPRD1 | P41143 | 12/20 | 0.77 |
| ▸ | OPRK1 | P41145 | 9/20 | 0.74 |
| ▸ | MRGPRX2 | Q96LB1 | 3/20 | 0.66 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.66 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.66 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dihydrocodeine SCHEMBL12402838 | 1.00 | OPRM1 (0.77) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| Dihydrocodeine SCHEMBL13380391 | 1.00 | OPRM1 (0.77) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| Dihydrocodeine SCHEMBL18569649 | 1.00 | OPRM1 (0.77) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| Dihydrocodeine SCHEMBL12960899 | 1.00 | OPRM1 (0.77) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| Dihydrocodeine SCHEMBL159237 | 1.00 | OPRM1 (0.77) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| Dihydrocodeine SCHEMBL10440393 | 1.00 | OPRM1 (0.77) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| Dihydrocodeine SCHEMBL12402837 | 1.00 | OPRM1 (0.77) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| Dihydrocodeine SCHEMBL6064584 | 1.00 | OPRM1 (0.77) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| Dihydrocodeine SCHEMBL6123622 | 1.00 | OPRM1 (0.77) | OPRM1OPRD1OPRK1MRGPRX2PDE4D | |
| Dihydrocodeine SCHEMBL14516219 | 1.00 | OPRM1 (0.77) | OPRM1OPRD1OPRK1MRGPRX2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017199014-A1 | TREATMENT OF OPIOID TOLERANCE | UNIVERSITY OF DUNDEE (GB) | 2017-11-23 | — | — | WO | claimed |
| US-20230065816-A1 | METHODS FOR PREVENTING AND REVERSING OPIOID ANALGESIC TOLERANCE IN SUBJECTS WITH CHRONIC PAIN | THE REASEARCH FOUND FOR SUNY (US) | 2023-03-02 | — | — | US | disclosed |
| US-11129825-B2 | Polysubunit opioid prodrugs resistant to overdose and abuse | ELYSIUM THERAPEUTICS, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-20210015848-A1 | COMPOSITIONS AND THEIR USE IN THE TREATMENT OF ENDOMETRIOSIS AND PAIN | RR MEDSCIENCES PTY LTD (AU) | 2021-01-21 | — | — | US | disclosed |
| EP-3749332-A1 | COMPOSITIONS AND THEIR USE IN THE TREATMENT OF ENDOMETRIOSIS AND PAIN | RR Medsciences Pty Ltd (AU) | 2020-12-16 | — | — | EP | disclosed |
| WO-2019153051-A1 | COMPOSITIONS AND THEIR USE IN THE TREATMENT OF ENDOMETRIOSIS AND PAIN | RR MEDSCIENCES PTY LTD (AU) | 2019-08-15 | — | — | WO | disclosed |
| US-20190183884-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | ELYSIUM THERAPEUTICS, INC. | 2019-06-20 | — | — | US | disclosed |
| WO-2017199014-A1 | TREATMENT OF OPIOID TOLERANCE | UNIVERSITY OF DUNDEE (GB) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210015848-A1 | COMPOSITIONS AND THEIR USE IN THE TREATMENT OF ENDOMETRIOSIS AND PAIN | ESR2, ESRRG, PTGES3 | OPRM1 61/4885OPRD1 20/4885OPRK1 4/4885 |
| US-11129825-B2 | Polysubunit opioid prodrugs resistant to overdose and abuse | OPRK1, OPRM1, CYP3A5 | OPRM1 2/4885OPRD1 13/4885OPRK1 1/4885 |
| US-20190183884-A1 | POLYSUBUNIT OPIOID PRODRUGS RESISTANT TO OVERDOSE AND ABUSE | OPRK1, OPRM1, CYP3A5 | OPRM1 2/4885OPRD1 13/4885OPRK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.